Novel agents for the therapy of varicella-zoster virus infections

Bibliography

• GILDEN DH, MAHALINGAM R, DUELAND AN et al:Herpes zoster: pathogenesis and latency. In: Progress in Medical Virology (Volume 6). Melnick JL (Ed.), Karger, Basel, Switzerland (1992):19–75.
   Google Scholar
• ARVIN AM: Varicella-zoster virus. an. Microbiol. Rev.(1996) 9:361–381.
   PubMed Web of Science ®Google Scholar
• •Useful overview on the clinical manifestations of varicella-zoster virus infection.
   Google Scholar
• HAAKE DA, ZAKOWSKI PC, HAAKE DL et al.: Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev. Infect. Dis. (1990) 12:788–797.
   PubMedGoogle Scholar
• SMEGO RA, JR., ASPERILLA MO: Use of acyclovir for varicella pneumonia during pregnancy. Obstet. Gynecol. (1991) 78:112–116.
   Web of Science ®Google Scholar
• TAYLOR CE, SVILAND L, PEARSON ADJ et al.: Virus infections in bone marrow transplant recipients: a three-year prospective study. J. Clin. Pathol. (1990) 43:633–637.
   PubMed Web of Science ®Google Scholar
• TAPPERO JVV, PERKINS BA, WENGER JD et al.: Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin. Microbiol. Rev. (1995) 8:440–450.
   PubMed Web of Science ®Google Scholar
• COCKERELL CJ: Human immunodeficiency virus infection and the skin: a crucial interface. Arch. Intern. Med. (1991) 151:1295–12303.
   PubMed Web of Science ®Google Scholar
• ENDERS G, MILLER E, CRADOCK-WATSON J et al.: of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet (1994) 343:1548–1551.
   PubMed Web of Science ®Google Scholar
• WEKSLER ME: Immune senescence. Ann. Neurol. (1994) 35 (Suppl.):S35–S37.
   Google Scholar
• McPHERSON RE: Herpes zoster opthalmicus and the immunocompromised host: a case report and review.. Am. Optom. Assoc. (1997) 68:527–538.
   PubMedGoogle Scholar
• MEYERS JD: Infection in recipients of bone marrow transplants. In: Current Clinical Topics in Infectious Diseases. Remington JS, Schwartz MN (Eds.), McGraw-Hill Book Co., New York, USA (1985):261–292.
   Google Scholar
• DUELAND AN, DEVLIN M, MARTIN JR et al: Fatalvaricella-zoster virus meningoradiculitis without skin involvement. Ann. Neurol. (1991) 29:569–572.
   PubMed Web of Science ®Google Scholar
• GILDEN DH, DUELAND AN, DEVLIN ME et al: Varicella-zoster virus reactivation without rash. J Infect. Dis. (1992) 1 66 (Suppl. 1):S30–S34.
   Google Scholar
• SNOECK R, GERARD M, SADZOT-DELVAUX C et al: Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in an AIDS patient. J Med. Virol. (1994) 42:338–347.
   PubMed Web of Science ®Google Scholar
• DE SILVA SM, MARK AS, GILDEN DH et al.: Zoster myelitis: improvement with antiviral therapy in two cases. Neurology (1996) 47:929–931.
   PubMed Web of Science ®Google Scholar
• LIONNET F, PULIK M, GENET P et al.: Myelitis due to varicella-zoster virus in two patients with AIDS: successful treatment with acyclovir. Clin. Infect. Dis. (1996) 22:138–140.
   PubMed Web of Science ®Google Scholar
• BATISSE M, ELIASZEWICZ M, ZAZOUN L et al.: Acuteretinal necrosis in the course of AIDS: study of 26 cases. AIDS (1996) 10:55–60.
   PubMed Web of Science ®Google Scholar
• FIGUEROA MS, GARABITO I, GUTIERREZ C et al.:Famciclovir for the treatment of acute retinal necrosis (AR N) syndrome. Am. J. Ophthalmol (1997)123:255–257.
   PubMed Web of Science ®Google Scholar
• LINNEMANN CC, JR., BIRON KK, HOPPENJANS WG et al: Emergence of acyclovir-resistant varicella-zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS (1990) 4:577–579.
   PubMed Web of Science ®Google Scholar
• JACOBSON MA, BERGER TG, FIKRIG S et al: Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. (1990) 112:187–191.
   PubMed Web of Science ®Google Scholar
• SMITH KJ, KAHLTER C, DAVIS C et al.: Acyclovir-resistant varicella zoster responsive to foscarnet. Arch. Dermatol. (1991) 127:1069–1071.
   PubMed Web of Science ®Google Scholar
• TALARICO CL, PHELPS WC, BIRON KK: Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J. Vim]. (1993) 67:1024–1033.
   Web of Science ®Google Scholar
• BOIVIN G, EDELMAN CK, PEDNEAULT L et al.: Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J. Infect. Dis. (1994) 170:68–75.
   PubMed Web of Science ®Google Scholar
• LACEY SF, SUZUTANI T, POWELL KL et al: Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction. J Gen. Virol. (1991) 72 :623–630.
   PubMed Web of Science ®Google Scholar
• IDA M, KAGEYAMA S, SATO H et al.: Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants. Antiviral Res. (1999) 40:155–166.
   PubMed Web of Science ®Google Scholar
• FILLET AM, DUMONT B, CAUMES E et al.: Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J. Med. Virol. (1998) 55:250–254.
   PubMed Web of Science ®Google Scholar
• PAHWA S, BIRON K, LIM W et al.: Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA (1988) 260:2879–2882.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, BERGER TG, GILSON I et al.: Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. (1991) 115:19–21.
   PubMed Web of Science ®Google Scholar
• VISSE B, DUMONT B, HURAUX JM, FILLET AM: Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect. Dis. (1998) 178 (Suppl. 1):S55–S57.
   Google Scholar
• VISSE B, HURAUX JM, FILLET AM: Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med. Virol. (1999) 59:84–90.
   PubMed Web of Science ®Google Scholar
• SAFRIN S, BERGER TG, GILSON I et al.: Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. Intern. Med. (1991) 115:19–21.
   PubMed Web of Science ®Google Scholar
• BRETON G, FILLET AM, KATLAMA C, BRICAIRE F, CAUMES E: Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin. Infect. Dis. (1998) 27:1525–1527.
   PubMed Web of Science ®Google Scholar
• BALFOUR HH, JR., KELLY JM, SUAREZ CS et al.: Acyclovir treatment of varicella in otherwise healthy children. J. Pediatr. (1990) 116:633–639.
   Google Scholar
• DUNKLE LM, ARVIN AM, WHITLEY RJ et al.: A controlled trial of acyclovir for chickenpox in normal children. N Engl. J. Med. (1991) 325:1539–1544.
   PubMed Web of Science ®Google Scholar
• BALFOUR HH, JR., DUNKLE LM, FEDER HM et al.: Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr. (1993) 120:627–633.
   Google Scholar
• WALLACE RM, BOWLER WA, MURRAY NB et al.: Treatment of adult varicella with oral acyclovir: a randomized, placebo controlled trial. Ann. Intern. Med. (1992) 117:358–363.
   PubMed Web of Science ®Google Scholar
• OGILVIE MM: Antiviral prophylaxis and treatment inchickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect. (1998) 3 6 (Suppl. 1):31–38.
   Google Scholar
• BROUSSARD RC, PAYNE K, GEORGE RB: Treatment ofvaricella pneumonia in pregnancy. Chest (1991) 99:1045–1047.
   PubMed Web of Science ®Google Scholar
• WHITLEY RJ, HILTY M, HAYNES R et al.: Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. (1982) 1:125–131.
   Google Scholar
• MESZNER Z, NYERGES G, BELL AR: Oral acyclovir to prevent dissemination of varicella in immunocom-promised children. J. Infect. (1993) 26:9–15.
   PubMed Web of Science ®Google Scholar
• CARCAO MD, LAU RC, GUPTA A, HUERTER H, KOREN G, KING SM: Sequential use of intravenous and oral acyclovir in the therapy of varicella in immunocom-promised children. Pediatric Infect. Dis. J. (1998) 17:626–631.
   PubMed Web of Science ®Google Scholar
• JOSEPH SG, OSER B: Complications of varicella in adults. J. Am. Osteopath. Assoc. (1993) 93:941-942, 946–947.
   Google Scholar
• BEAN B, BRAUN C, BALFOUR JR. HH: Acyclovir therapy for acute herpes zoster. Lancet (1982) 2(8290):118–121.
   Google Scholar
• PETERSLUND NA, SEYER-HANSEN K, IPJEN J et al: Acyclovir in herpes zoster. Lancet (1981) 2 (8250:827–830.
   PubMed Web of Science ®Google Scholar
• WOOD MJ, OGAN PH, McKENDRICK MW etal: Efficacy of oral acyclovir treatment of acute herpes zoster. Am. J Med. (1988) 85 (Suppl. 2A):79–83.
   Google Scholar
• COBO LM, FOULKS GN, LIESEGANG T: Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology (1986) 93:763–770.
   PubMed Web of Science ®Google Scholar
• BOWSHER D: The management of postherpetic neuralgia. Postgrad. Med. J (1997) 73:623–629.
   PubMed Web of Science ®Google Scholar
• CHOO PW, GAUL K, DONAHUE JG, WALKER AM, SPIEGELMAN D, PLATT R: Risk factors for postherpetic neuralgia. Arch. Intern. Med. (1997) 157:1217–1224.
   PubMed Web of Science ®Google Scholar
• SCHAMDER K: Postherpetic neuralgia in immunocom-petent elderly people. Vaccine (1998) 16:1768–1770.
   PubMed Web of Science ®Google Scholar
• HUFF C, DRUCKER JL, CLEMMER A et al: Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med. Vim]. (1993) (Suppl. 1):93–96.
   Google Scholar
• JACKSON JL, GIBBONS R, MEYER G et al: The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch. Intern. Med. (1997) 157:909–912.
   PubMed Web of Science ®Google Scholar
• ESMANN V, KROON S, PETERSLUND NA: Prednisolone does not prevent postherpetic neuralgia. Lancet (1987) 2(8551):126–129.
   PubMed Web of Science ®Google Scholar
• WOOD MJ, JOHNSON RW, McKENDRICK MW et al: A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl. J. Med. (1994) 330:896–900.
   PubMed Web of Science ®Google Scholar
• WHITLEY RJ, WEISS H, GNANN JW, JR. et al.: Acyclovir with and without prednisone for the treatment of herpes zoster. Ann. Intern. Med. (1996) 125:376–383.
   Google Scholar
• BALFOUR JR HH, BEAN B, LASKIN OL et al: Acyclovir halts progression of herpes zoster in immunocompro-mised patients. N Engl. J. Med. (1983) 308:1448–1453.
   PubMed Web of Science ®Google Scholar
• SHEPP D, DANDLIKER PS, MEYERS JD: Treatment of varicella-zoster virus in severely immunocompro-mised patients: a randomized comparison of acyclovir and vidarabine. N Engl. J Med. (1986) 314:208–212.
   PubMed Web of Science ®Google Scholar
• WHITLEY RJ: Therapeutic approaches to varicella-zoster virus infections. J Infect. Dis. (1992) 166 (Suppl. 1):S51–S57.
   Google Scholar
• WHITLEY RJ, GNANN JR JW, HINTHORN D eta].: Dissemi-nated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. Infect. Dis. (1992) 165:450–455.
   Google Scholar
• BANERJEE A: Zona in children. Arch. Pediatr. (1998)5:199–203.
   PubMed Web of Science ®Google Scholar
• KAKOUROU T, THEODORIDOU M, MOSTROU G, SYRIOPOULOU V, PAPADOGEORGAKI H, CONSTANTO-POULOS A: Herpes zoster in children. J. Am. Acad. Dermatol. (1998) 39:207–210.
   PubMed Web of Science ®Google Scholar
• LEAUTEZ S, BANI-SADR F, BILLAUD E, RAFFI F:Secondary prophylaxis for herpes zoster with oral acyclovir in HIV patients. Pathol. Biol. Paris (1999) 47:570–572.
   PubMed Web of Science ®Google Scholar
• DULLAERT H, MAUDGAL PC, LEYS A et al: Bromov-inyldeoxyuridine treatment of outer retinal necrosis due to varicella-zoster virus: a case report. Bull. Soc. Beige Ophtalmol (1997) 262:107–113.
   Google Scholar
• WILDIERS J, DE CLERCQ E: Or al (E)-5 -(2 -br o m oviny1)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients. Eur. J. Cancer Clin. Oncol. (1984) 4:471–476.
   Google Scholar
• BENOIT Y, LAUREYS G, DELBEKE M-J et al.: Oral BVDUtreatment of varicella and zoster in children with cancer. Eur.J. Pediatr. (1985) 143:198–202.
   PubMed Web of Science ®Google Scholar
• WUTZLER P, DE CLERCQ E, WUTKE K etal.: Oral brivudin VS. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a random-ized double-blind trial. J. Med. Virol. (1995) 46:252–257.
   Google Scholar
• HEIDL M, SCHOLZ H, DORFFEL W, HERMANN J: Antiviral therapy of varicella-zoster virus infection in immuno-compromised children. A prospective randomized study of acyclovir versus brivudin. Infection (1991) 19:401–405.
   Google Scholar
• WAGSTAFF AJ, FAULDS D, GOA KL: Acyclovir: areappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 47:153–205.
   PubMed Web of Science ®Google Scholar
• WHITLEY RJ, GNANN JR. JW: Acyclovir: a decade later. NEngl. J. Med. (1992) 327:782–789.
   PubMed Web of Science ®Google Scholar
• DE MIRANDA P, BLUM MR: Pharmacokinetics ofacyclovir after intravenous and oral administration. J Antimicrob. Chemother. (1983) 12 (Suppl. B):29–37.
   Google Scholar
• WELLER S, BLUM M, DOULETTE M et al.: Pharmacoki-netics of the acyclovir prodrug, valaciclovir, after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol Ther. (1993) 54:595–605.
   PubMed Web of Science ®Google Scholar
• PERRY CM, FAULDS D: Valaciclovir: a review of itsantiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs (1996) 52:754–772.
   PubMed Web of Science ®Google Scholar
• •Detailed review on the pharmacology and clinical use of valaciclovir.
   Google Scholar
• BEUTNER KR, FRIEDMAN DJ, PORSZPANIAK C et al.:Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. (1 9 9 5) 39:1546-1553.
   Google Scholar
• HERNE K, CIRELLI R, LEE P et al.: Antiviral therapy ofacute herpes zoster in older patients. Drugs Aging (1996) 8:97–112.
   PubMed Web of Science ®Google Scholar
• BOYD MR, BACON TH, SUTTON D et al.: Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)g-uanine (BRL 39123) in cell culture. Antimicrob. Agents Chemother. (1987) 31:1238–1242.
   PubMed Web of Science ®Google Scholar
• VERE HODGE RA: Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-y1) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. (1989) 33:223–229.
   PubMed Web of Science ®Google Scholar
• EARNSHAW DL, BACON TH, DARLISON SJ et al.: Penciclovir: mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus (HSV-1), HSV-2 and varicella-zoster virus. Antimicrob. Agents Chemother. (1992) 36:2747–2757.
   PubMed Web of Science ®Google Scholar
• VERE HODGE RA: Famciclovir and penciclovir: the mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. (1993) 4:67–84.
   Web of Science ®Google Scholar
• •Useful overview on the mechanism of action of famciclovir.
   Google Scholar
• TYRING S, BARBARASH RA, NAHLIK JE et al.: Famciclovirfor the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a random-ized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1995) 123:89–96.
   PubMed Web of Science ®Google Scholar
• DEGREEF H, FAMCICLOVIR HERPES ZOSTER CLINICAL STUDY GROUP: Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment uncomplicated herpes zoster in immunocompetent patients. Int. J. Antimicrob. Agents (1994) 4:241–246.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E, HOLY A, ROSENBERG I et al.: A novel selective broad-spectrum anti-DNA virus agent. Nature (1986) 323:464–467.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol (1993) 3:85–96.
   Web of Science ®Google Scholar
• NAESENS L, SNOECK R, ANDREI G et al.: HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Chemother. (1997) 8:1–23.
   Web of Science ®Google Scholar
• •Detailed review on the antiviral action of cidofovir and adefovir.
   Google Scholar
• HITCHCOCK MJM, JAFFE HS, MARTIN JC et al.: Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemother. (1996) 7:115–127.
   Web of Science ®Google Scholar
• SAFRIN S, CHERRINGTON J, JAFFE HS: Clinical use of cidofovir. Rev. Med. Virol (1997) 7:145–156.
   PubMed Web of Science ®Google Scholar
• •Interesting overview of the potential clinical applications of cidofovir.
   Google Scholar